Compare Msci Inc (MSCI) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Msci Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Msci Inc trades at $554.53 (market cap $40.32B), while State Street SPDR S&P Biotech ETF trades at $159.85. The key difference: Msci Inc pays a 1.48% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Msci Inc nearer its low. Which is the better fit depends on your goals.
| MSCI | XBI | |
|---|---|---|
Market Cap | $40.32B | — |
Sector | Financials | Broad Market / Factor |
52-Week High | $643.83 | $169.55 |
52-Week Low | $511.84 | $93.43 |
Enterprise Value | $46.48B | — |
Dividend Yield | 1.48% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSCI trades at $551.39, down 3.77% over 24 hours, amid a bearish technical signal. The stock shows strong fundamentals with revenue growth to $3.13B in 2025 and a net income margin of 40.73%, though it faces a high P/E of 30.32. Recent developments include the acquisition of First Street and a strategic partnership with UBS, enhancing its private markets platform. Cash flow turned positive in 2025, but high debt levels and a negative equity position pose risks.
The outlook is mixed: analyst consensus is bullish with a $728.14 price target, but technical indicators signal caution. Upside potential hinges on continued earnings beats and revenue growth, while risks include market volatility and execution challenges. Investors should weigh strong profitability against valuation concerns and debt load.
XBI trades at $161.97, down 1.12% today, with technical indicators showing mixed signals amid a bearish overall trend. The ETF holds over 150 biotech companies and has rallied 76% in the past year, driven by M&A activity and positive clinical trial catalysts. Analyst coverage remains limited with a single hold rating, while recent news highlights sector optimism around cancer vaccine breakthroughs and improved capital access.
Outlook remains cautiously optimistic with potential for 8-14% returns over 6-12 months, though high volatility and regulatory risks persist. Key opportunities include ongoing pharmaceutical M&A and innovation in immunotherapy, while risks center on sector-specific volatility and policy uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Msci Inc
MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.
Read more on MSCI →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
